Appropriate risk classification and low-dose rituximab can help prevent antibody-associated rejection in ABO-compatible kidney transplants

被引：0
|
作者：
Fukuda, Miruzato [1 ]
Yokoyama, Takayoshi [1 ]
Miki, Katsuyuki [2 ]
Tanaka, Kiho [1 ]
Nakamura, Yuki [2 ]
Ishii, Yasuo [1 ]
机构：
[1] Toranomon Gen Hosp, Ctr Renal Surg, Tokyo, Japan
[2] Toranomon Hosp Kajigaya, Ctr Renal Surg, Kawasaki, Kanagawa, Japan
来源：
TRANSPLANTATION | 2024年 / 108卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
400.1
引用
收藏
页码：304 / 304
页数：1
相关论文
共 15 条
  • [1] Appropriate risk classification and low-dose rituximab can help prevent antibody-associated rejection in ABO-compatible kidney transplants.
    Fukuda, Miruzato
    Yokoyama, Takayoshi
    Miki, Katsuyuki
    Tanaka, Kiho
    Nakamura, Yuki
    Ishii, Yasuo
    TRANSPLANTATION, 2024, 108 (9S)
  • [2] Outcome Comparison of ABO-Incompatible Kidney Transplantation With Low-Dose Rituximab and ABO-Compatible Kidney Transplantation: A Single-Center Experience
    Hatakeyama, S.
    Fujita, T.
    Murakami, R.
    Suzuki, Y.
    Sugiyama, N.
    Yamamoto, H.
    Okamoto, A.
    Imai, A.
    Tobisawa, Y.
    Yoneyama, T.
    Mori, K.
    Yoneyama, T.
    Hashimoto, Y.
    Koie, T.
    Narumi, S.
    Ohyama, C.
    TRANSPLANTATION PROCEEDINGS, 2014, 46 (02) : 445 - 448
  • [3] Chronic Antibody Mediated Rejection (cABMR) in ABO-Incompatible and ABO-Compatible Kidney Transplants: A Single US Center Experience
    Sethi, S.
    Vo, A.
    Huang, E.
    Varanasi, L.
    Choi, J.
    Peng, A.
    Najjar, R.
    Jordan, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 412 - 412
  • [4] Low-dose rituximab to salvage renal transplants from refractory antibody-mediated rejection
    Mulley, William R.
    Tait, Brian D.
    Hudson, Fiona
    Skene, Alison M.
    Dowling, John P.
    Kerr, Peter G.
    Kanellis, John
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 238 - 238
  • [5] Early Antibody-Mediated-Rejection in ABO-Incompatible Renal Transplant Recipients Can Be Successfully Treated with Comparable Clinical Outcomes to ABO-Compatible Transplants
    Mahendran, A. O.
    Mohan, S.
    Watkins, A. C.
    Stokes, M. B.
    Crew, J.
    Cohen, D.
    Ratner, L. E.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 418 - 418
  • [6] Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis
    Gulati, Kavita
    Edwards, Helena
    Prendecki, Maria
    Cairns, Thomas D.
    Condon, Marie
    Galliford, Jack
    Griffith, Megan
    Levy, Jeremy B.
    Tam, Frederick W. K.
    Tanna, Anisha
    Pusey, Charles D.
    McAdoo, Stephen P.
    KIDNEY INTERNATIONAL, 2021, 100 (06) : 1316 - 1324
  • [7] Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: a Chinese case series
    Liu, Lin
    Lu, Haitao
    Zou, Guming
    Wang, Haifeng
    Li, Jing
    Yang, Yue
    Zhang, Jian
    Wang, Xueling
    Li, Wenge
    Zhuo, Li
    BMC NEPHROLOGY, 2023, 24 (01)
  • [8] Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: a Chinese case series
    Lin Liu
    Haitao Lu
    Guming Zou
    Haifeng Wang
    Jing Li
    Yue Yang
    Jian Zhang
    Xueling Wang
    Wenge Li
    Li Zhuo
    BMC Nephrology, 24
  • [9] A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants
    Flechner, SM
    Goldfarb, DA
    Fairchild, R
    Modlin, CS
    Fisher, R
    Mastroianni, B
    Boparai, N
    O'Malley, KJ
    Cook, DJ
    Novick, AC
    TRANSPLANTATION, 2000, 69 (11) : 2374 - 2381
  • [10] Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients
    Tomita, Yusuke
    Iwadoh, Kazuhiro
    Ogawa, Yuichi
    Miki, Katsuyuki
    Kato, Yojiro
    Kai, Kotaro
    Sannomiya, Akihito
    Koyama, Ichiro
    Kitajima, Kumiko
    Nakajima, Ichiro
    Fuchinoue, Shohei
    PLOS ONE, 2019, 14 (10):
12